Bone marrow-derived stem cell therapy (FCB-Pharmicell)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBone marrow-derived stem cell therapy (FCB-Pharmicell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFcb-PharmicellSeoul National University Alumni Association In The U.S.A. Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFcb-PharmicellSeoul National University Alumni Association In The U.S.A. Inc
Active IndicationsN/A
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksN/A